The distinction between these two pathways may help to explain the difference between outcomes for younger and older patients — PA in younger patients is more likely to be caused by K: B fusion and 5 - year survival is generally high; PA in older patients is more likely to be caused by
BRAF point mutations and 5 - year survival is generally lower.
Not exact matches
In fact, there are two specific mechanisms for activation of
BRAF implicated in PA formation: by fusion of the gene with nearby gene KIAA1549 (K: B fusion) or by
point mutations of the
BRAF gene itself.
She also
points out that while the combination of dabrafenib and trametenib earned FDA approval against lung cancer with
BRAF V600
mutation in the United States, the combination hasn't yet earned such approval in other countries, and these guidelines are meant to guide care not just in the United States, but internationally.